News Interim report for 1H 2023 Please read the full announcement in PDF Attachment 2023_54_Q22023_CompanyAnnouncement Continue Reading Previous Novartis remibrutinib Phase III trials met their primary endpoints and showed rapid symptom control in chronic spontaneous urticariaNext Novozymes delivers results within expectations in the first half of 2023 and narrows the full year outlook Related Stories Media Services News BOMESI Foundation Opens Fifth Accelerator Cohort For Diverse-Owned Media Publishers And Creators News Ynvisible Advances Commercial Program with Sapphiros, Announces CFO Appointment and Adoption of Semi-Annual Financial Reporting AI Agents News Security Hexnode Unveils Hexnode Synapse, Bringing Agentic Orchestration To IT And Security Operations News Airwheel SE3SX AI Wheel Luxury Suitcase Wins 2026 WGA for Smart Electric Riding Carry-On Hand Luggage News Syntheia Signs Definitive Agreement for Sale of Call Center Assets and Announces Shares for Debt Transaction News CEO.CA’s Inside the Boardroom: “The Path Has Never Been More Clear”: Highland Copper Lands State Grant
